ERBB2 and breast cancer: In particular, AKT1 p.E17K showed a higher mutation frequency (7% versus 0%, FDR < 0.05) in the HR+/HER2− breast cancer subgroup in our cohort than in the TCGA cohort (Supplementary Fig. 5d, top left).